ABL and RDI collaborate to enhance HIV patient management

Dear HIV-TRePS user / RDI subscriber,

We are pleased to announce that we are collaborating with ABL to enable users of their TherapyEdge(R) health management software to use HIV-TRePS seamlessly, without manual entry of the data required by TRePS for its predictions. Here is the press release that has gone out today.

Kind regards,

ABL and RDI collaborate to enhance HIV patient management

HIV-TRePS now accessible seamlessly from TherapyEdge(R)

BUSINESSWIRE - LONDON AND LUXEMBOURG (Monday 2nd June 2014): Advanced Biological Laboratories (ABL) S.A. and the HIV Resistance Response Database Initiative (RDI) are pleased to announce their collaboration to enhance HIV patient management. As the first milestone of the collaboration, data stored on ABL's health management system, TherapyEdge(R), can now be automatically uploaded to RDI's HIV Treatment Response Prediction System (HIV-TRePS), providing the physician with predictions of how their patient will respond to any combination of HIV drugs, in a matter of seconds.

"For busy physicians at clinics like ours, trying to optimize the management of HIV for large numbers of infected individuals, this is a major step forward", commented Prof Ian Sanne, (Right To Care, South Africa). "When a patient requires a change to their therapy we can now obtain predictions of how they will respond to alternative regimens automatically and directly through our TherapyEdge(R) electronic record and database system, so we can make fast, informed choices".

TherapyEdge(R) is an intelligent, patient management system for healthcare professionals caring for people with potentially life-threatening chronic diseases, such as HIV infection. It assimilates longitudinal patient data, state of the art medical and clinical trial information and international and national guidelines.

HIV-TRePS, harnesses the predictive power of computational models developed using data from tens of thousands of patients to estimate the probability of success of any combination of antiretroviral drugs. It makes these predictions from the patient's individual data - the viral load (the amount of virus in the bloodstream), the CD4 count (a measure of the immune system), the drugs used to treat them in the past and, if available, the viral genotype (the genetic code of HIV). Today's development means that these data can be sent to HIV-TRePS automatically from TherapyEdge(R), delivering the systems' predictions to the physician quickly and easily.

"We are very pleased to be collaborating with RDI to enhance physicians' access to HIV-TRePS", commented Dr Chalom Sayada CEO of ABL. "Studies suggest the system can help physicians avoid failing regimens and even reduce costs, so facilitating its use as part of our patient management system could bring significant patient benefits."

HIV-TRePS will also continue to be available to all healthcare professionals, free of charge over the Internet via the RDI's web site. Use of the system in this way requires that the physician enters their patient's data manually.

"This is an exciting and highly logical step forward, capitalizing on the complementarity of our systems in a way that I believe is a model for the future management of many different medical conditions", commented Dr Brendan Larder, Scientific Chair of the RDI. "We are hopeful that the collaboration will also accelerate the collection of outcome data and enable us to develop new and further improved versions of HIV-TRePS."

About RDI

The RDI is an independent, not-for-profit international research collaboration set-up in 2002 with the mission to improve the clinical management of HIV infection through the application of bioinformatics to HIV drug resistance and treatment outcome data. Over the 12 years since its inception, the RDI has worked with many of the leading clinicians and scientists in the world to develop the world's largest database of HIV drug resistance and treatment outcome data, containing information from over 150,000 patients in more than 30 countries.

HIV-TRePS is an experimental system intended for research use only. The predictions of the system are not intended to replace professional medical care by a qualified medical practitioner and consequently the RDI does not accept any responsibility for the selection of drugs, the patient's response to treatment or differences between the predictions and patients' responses.

About ABL

Advanced Biological Laboratories (ABL), S.A., is a Medical Data Technology company founded in 2000 as a spin-off from CRP-Sante Luxembourg. ABL took control of TherapyEdge, Inc. in 2004 and in 2013 acquired the rights to all viral hepatitis B & C related assets from EVIVAR MEDICAL, respectively. ABL has a comprehensive suite of healthcare management tools, including TherapyEdge(R), ViroScore(R), SeqHepB, DeepChek(R), VisibleChek(R) and HepatiC(TM), which are used for data and patient management, monitoring and personalized reporting applications. In 2012, some of ABL's products received CE-marking for IVD use. ABL's products offer infectious disease clinicians and virology laboratories optimal and efficient IT solutions, for sequencing, clinical genotyping, and drug resistance analysis, including powerful fully integrated databases and analysis systems combining standard and high-throughput Next Generation Sequencing data. More at www.ablsa.com.

All trademarks used or mentioned in this release are protected by law.


Advanced Biological Laboratories
Dr Chalom Sayada, +352 2638 8921

RDI (HIV Resistance Response Database Initiative)
Dr Andrew Revell, +44 207 226 7314
Executive Director

Date published: 2nd June 2014


Join the RDI mailing list

Enter your email address below to start receiving the RDI newsletter.

You can unsubscribe at any time. View the RDI privacy policy.